Literature DB >> 12358603

Factor VII mutant V154G models a zymogen-like form of factor VIIa.

Raffaella Toso1, Francesco Bernardi, Theresa Tidd, Mirko Pinotti, Rodney M Camire, Giovanna Marchetti, Katherine A High, Eleanor S Pollak.   

Abstract

Proteolytic cleavage of the peptide bond between Arg(152) and Ile(153) converts the procoagulant protein Factor VII (FVII) to an activated two-chain form (FVIIa). The formation of a salt bridge between Ile(153) and Asp(343) drives the conversion of FVIIa from being zymogen-like to the active form. In the present paper, we describe the novel FVII mutant V154G (Val(154)-->Gly mutation; residue 17 in the chymotrypsin numbering system), found in three FVII-deficient patients, which models a zymogen-like form of FVIIa. Recombinant V154G FVIIa, although normally cleaved, shows markedly reduced activity towards peptidyl substrate and undetectable activity towards macromolecular substrates. Susceptibility of Ile(153) to chemical modification, in either the presence or the absence of tissue factor (TF), suggests that the reduced V154G FVIIa activity is caused by impaired salt-bridge formation, thus resulting in a zymogen-like FVIIa form. The TF-mediated protection from chemical modification of V154A indicated that Gly(154) is responsible for this peculiar feature, and suggests that this region, proximal to the heavy chain N-terminus, is directly involved in the conversion of FVII into FVIIa. V154G FVII was exploited to study the FVII-TF interaction, together with three additional FVII variants that were expressed to serve as models for different FVII forms. The comparison of binding affinities of full-length TF after relipidation in L-alpha-phosphatidylcholine for the zymogen FVII (Arg(152)-->Gln, K (d)=1.04+/-0.27 nM), inactive FVIIa (Ser(344)-->Ala, K (d)=0.27+/-0.06 nM) and a zymogen-like FVIIa (V154G, K (d)=1.15+/-0.16 nM) supports the hypothesis that preferential binding of TF to active FVIIa is insufficient to drive the 10(5)-fold enhancement of FVIIa activity. In addition, the inability of V154G FVIIa to accommodate an inhibitor in the active site, indicating an improperly shaped specificity pocket, would explain the low activity of the zymogen-like form of FVIIa, which is predominant in the absence of TF.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12358603      PMCID: PMC1223097          DOI: 10.1042/BJ20020888

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  42 in total

1.  Selection and characterization of a new class of peptide exosite inhibitors of coagulation factor VIIa.

Authors:  M S Dennis; M Roberge; C Quan; R A Lazarus
Journal:  Biochemistry       Date:  2001-08-14       Impact factor: 3.162

2.  Factor VIIa modified in the 170 loop shows enhanced catalytic activity but does not change the zymogen-like property.

Authors:  K Soejima; J Mizuguchi; M Yuguchi; T Nakagaki; S Higashi; S Iwanaga
Journal:  J Biol Chem       Date:  2001-02-02       Impact factor: 5.157

3.  A cyclic pentapeptide derived from the second EGF-like domain of Factor VII is an inhibitor of tissue factor dependent coagulation and thrombus formation.

Authors:  Lars Orning; Peter M Fischer; Chih-Kao Hu; Erik Agner; May Engebretsen; Mette Husbyn; Lizette B Petersen; Una Orvim; Miguel Llinas; Kjell S Sakariassen
Journal:  Thromb Haemost       Date:  2002-01       Impact factor: 5.249

4.  Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity.

Authors:  E Persson; M Kjalke; O H Olsen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

5.  The reaction between bovine brain tissue factor and factors VII and X.

Authors:  Y Nemerson
Journal:  Biochemistry       Date:  1966-02       Impact factor: 3.162

6.  On the size of the active site in proteases. I. Papain.

Authors:  I Schechter; A Berger
Journal:  Biochem Biophys Res Commun       Date:  1967-04-20       Impact factor: 3.575

7.  Substitution of valine for leucine 305 in factor VIIa increases the intrinsic enzymatic activity.

Authors:  E Persson; H Bak; O H Olsen
Journal:  J Biol Chem       Date:  2001-06-01       Impact factor: 5.157

8.  Role of residue Phe225 in the cofactor-mediated, allosteric regulation of the serine protease coagulation factor VIIa.

Authors:  R J Petrovan; W Ruf
Journal:  Biochemistry       Date:  2000-11-28       Impact factor: 3.162

9.  A frequent human coagulation Factor VII mutation (A294V, c152) in loop 140s affects the interaction with activators, tissue factor and substrates.

Authors:  Raffaella Toso; Mirko Pinotti; Katherine A High; Eleanor S Pollak; Francesco Bernardi
Journal:  Biochem J       Date:  2002-04-15       Impact factor: 3.857

10.  Twenty two novel mutations of the factor VII gene in factor VII deficiency.

Authors:  K Wulff; F H Herrmann
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

View more
  6 in total

1.  Disulfide locked variants of factor VIIa with a restricted beta-strand conformation have enhanced enzymatic activity.

Authors:  Henry R Maun; Charles Eigenbrot; Helga Raab; David Arnott; Lilian Phu; Sherron Bullens; Robert A Lazarus
Journal:  Protein Sci       Date:  2005-05       Impact factor: 6.725

2.  Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo.

Authors:  Paris Margaritis; Elise Roy; Armida Faella; Harre D Downey; Lacramioara Ivanciu; Giulia Pavani; Shangzhen Zhou; Ralph M Bunte; Katherine A High
Journal:  Blood       Date:  2011-02-16       Impact factor: 22.113

3.  Augmented intrinsic activity of Factor VIIa by replacement of residues 305, 314, 337 and 374: evidence of two unique mutational mechanisms of activity enhancement.

Authors:  Egon Persson; Helle Bak; Anette Østergaard; Ole H Olsen
Journal:  Biochem J       Date:  2004-04-15       Impact factor: 3.857

Review 4.  Structure-Function Relationship of the Interaction between Tissue Factor and Factor VIIa.

Authors:  Joshua M Gajsiewicz; James H Morrissey
Journal:  Semin Thromb Hemost       Date:  2015-09-26       Impact factor: 4.180

Review 5.  Biochemical, molecular and clinical aspects of coagulation factor VII and its role in hemostasis and thrombosis.

Authors:  Francesco Bernardi; Guglielmo Mariani
Journal:  Haematologica       Date:  2021-02-01       Impact factor: 9.941

6.  Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa.

Authors:  S R Lentz; S Ehrenforth; F Abdul Karim; T Matsushita; K N Weldingh; J Windyga; J N Mahlangu
Journal:  J Thromb Haemost       Date:  2014-07-16       Impact factor: 5.824

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.